Plain-English translation of NCT05282108 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study compares two versions of a medication called imatinib—one brand-name version (®) and one generic version (®)—in patients newly diagnosed with chronic myeloid leukemia. Researchers will follow patients taking either medication for 12 months in their regular clinics to see how well the treatment controls the disease and whether patients experience any side effects. This real-world comparison will help doctors understand if both versions work equally well for patients.
Generic medications are often less expensive than brand-name drugs, but doctors and patients need to know that a generic version works just as well and is just as safe. This study will provide evidence about whether this medication works equally well regardless of which version patients take.
You likely qualify if…
You likely don't qualify if…
You will take one of the two medications as part of your regular cancer care—no extra visits or tests beyond what your doctor normally does are required. Your medical team will simply keep track of how you respond to the medication and any side effects you experience over 12 months, using information from your regular clinic appointments.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Egypt
Sponsor
Hikma Pharmaceuticals LLC
Enrollment target
~240 participants
Started
July 2022
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ruba A Jaber
Hikma Pharmaceuticals LLC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.